Cardiovascular alpha 2-receptors.
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000345:Affinity Labels / Q000378:metabolism; D000818:Animals; D001794:Blood Pressure; D001921:Brain / Q000502:physiology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002320:Cardiovascular Physiological Phenomena; D006160:Guanosine Triphosphate / Q000494:pharmacology; D006339:Heart Rate; D006801:Humans; D007650:Ketanserin; D007668:Kidney / Q000502:physiology; D009131:Muscle, Smooth, Vascular / Q000502:physiology; D010879:Piperazines / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000502:physiology*; D013570:Synaptic Membranes / Q000502:physiology; D014316:Tritium; D014661:Vasoconstriction
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000345:Affinity Labels; D002121:Calcium Channel Blockers; D010879:Piperazines; D010880:Piperidines; D011942:Receptors, Adrenergic, alpha; D014316:Tritium; D006160:Guanosine Triphosphate; D007650:Ketanserin; C015568:urapidil; D011224:Prazosin